Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in ...

Ltd., widely known as Baurs, a leading conglomerate with diversified business interests in Sri Lanka and a pioneer and ...

Stock market investors panicked and the CSE was slightly volatile yesterday due to the US tariff revision on Sri Lankan ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, ...

The global biosimilars market is driven by less expensive alternatives made possible by the major biologics' patents expiring. The demand for reasonably ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 ...

Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...